va luated. In another drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a single dose of a P-gp inhibitor was co-administered in healthy subjects.
Everolimus: Avoid the concomitant use of venetoclax and everolimus as everolimus levels may be increased. If concomitant use of these drugs is required, administer everolimus at least 6 hours before venetoclax. Monitor patients for signs and symptoms of everolimus toxicity. Venetoclax is an inhibitor of P-glycoprotein (P-gp) and everolimus is a P-gp substrate with a narrow therapeutic index; these agents may interact in the gastrointestinal tract.
Ezetimibe; Simvastatin: Avoid the concomitant use of venetoclax and simvastatin. Venetoclax is a substrate of P-glycoprotein (P-gp) and may be a P-gp inhibitor at therapeutic dose levels in the gut; simvastatin is a substrate and an inhibitor of P-gp. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day) and consider administering simvastatin at least 6 hours before venetoclax. If simvastatin is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Felbamate: Avoid the concomitant use of venetoclax and felbamate; venetoclax levels may be decreased and its efficacy reduced. Venetoclax is a CYP3A4 substrate and felbamate is a moderate CYP3A4 inducer. Consider alternative agents. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were decreased by 42% and 71%, respectively, following the co-administration of multiple doses of a strong CYP3A4 inducer. Use of venetoclax with a moderate CYP3A4 inducer has not been eva luated.
Felodipine: Avoid the concomitant use of venetoclax and felodipine; venetoclax is a substrate of P-glycoprotein (P-gp) and felodipine is an inhibitor of P-gp. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If felodipine is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Flibanserin: Avoid the concomitant use of venetoclax and flibanserin; venetoclax is a substrate of P-glycoprotein (P-gp) and flibanserin is an inhibitor of P-gp. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If flibanserin is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp in |
